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Since the first description (1) of Helicobacter
pylori and the acceptance of its role in the
pathogenesis of peptic ulcer disease (PUD) (2),
different regimens to eradicate this micro-
organism have been used in clinical practice (3).
Metronidazole has frequently been used as a com-
ponent in these treatment regimens. H. pylori
resistance to metronidazole has been associated
with treatment failure (4-7). Recently, an increase
of metronidazole resistance has been reported
from different parts of the world (8-13). This
retrospective study describes the prevalence of
primary metronidazole resistance occurring in H.
pylori strains in 1993 and 1996 in three regional
hospitals in the northern part of the Netherlands
and in 1994-95 in one of these hospitals.
Sampling
All cultures of antral biopsy specimens
yielding growth of H. pylori in the study period
were considered for evaluation. Previous anti-
H. pylori treatment was the only reason for
exclusion. All 1,037 H. pylori strains evaluated
were isolated from different patients. Biopsy
specimens for culture were taken within 3 cm of
the pylorus. Endoscopes and biopsy equipment
were thoroughly cleaned with a detergent and
disinfected with 2% glutaraldehyde in an auto-
matic washing machine between procedures. Cul-
ture was performed as described elsewhere (14).
Susceptibility Testing
Susceptibility to metronidazole was deter-
mined by disk diffusion in 1993 and the Epilipso-
meter-test (E-test) in 1994-1996. For these tests,
plates were injected with a suspension adjusted
to a turbidity approximating that of a McFarland
No. 3 standard (15). For disk diffusion, a 5-mg
disk (Mast Laboratories, Liverpool, United King-
dom) was used and read after at least 3 days of
incubation. Strains with an inhibition zone of 10
mm or more were regarded as susceptible (16).
The E-test (AB Biodisk, Solna, Sweden)(17) was
performed according to the instructions of the
manufacturer and read after at least 3 days.
The strains were considered metronidazole
resistant when the minimum inhibitory con-
centration was above 8  g/ml (18).
To test the equivalence of the two methods of
susceptibility testing, a prospective study com-
pared the E-test and disk diffusion. In 124
different H. pylori strains, results were con-
current in all but six.
Prevalence of Metronidazole-Resistant H.
pylori
In one of the hospitals (Hospital C), data were
available on endoscopic diagnosis, age, and
ethnic background of the patients from whom the
strains were isolated in 1993 and 1996. In this
hospital, it was possible to compare the prevalence
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The prevalence of primary metronidazole resistance of Helicobacter pylori was studied
in one Dutch hospital from 1993 to 1996 and in two additional Dutch hospitals in 1993 and
1996. All cultures of antral biopsy specimens yielding H. pylori in the study period were
evaluated, except those from patients who had received anti-H. pylori treatment; 1,037 H.
pylori strains, all from different patients were included. Metronidazole resistance was
determined by disk diffusion in 1993 and by Epilipsometer-test in 1994 to 1996.
Metronidazole resistance increased from 7% (18/245) in 1993 to 32% (161/509) in 1996.
More patients with nonulcer dyspepsia and more non-Western European patients were
seen in 1996 than in 1993, but age and sex differences were not observed. A comparable
increase in metronidazole resistance was observed in both nonulcer dyspepsia patients
and peptic ulcer patients, and the prevalence of metronidazole resistance in Western
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of metronidazole resistance in PUD patients with
that in nonulcer dyspepsia (NUD) patients and to
look at resistance rates in patients of different
ethnic backgrounds. Statistical analysis was per-
formed by Fisher’s exact test on binomial data
and Student’s t test on continuous data. Differ-
ences were considered significant when p < 0.05.
The number of H. pylori strains isolated in
the three  hospitals was 245 in 1993 and 509 in
1996. In Hospital C, an additional 137 strains
from 1994 and 146 strains from 1995 were
studied. Looking at the sex of the study popu-
lation, we found a male-to-female ratio in 1993 of
1.75:1, in 1994 of 1.36:1, in 1995 of 1:1, and in
1996 of 1.18:1 (the total male-to-female ratio was
1.28:1). The proportion of women in the popu-
lation examined was higher in 1996 (46%) than in
1993 (36%)(p = 0.02). The prevalence of metroni-
dazole resistance did not differ, however, between
men and women. The prevalence of metronidazole
resistance increased significantly from 1993 to
1996 in the total sample group (Figure 1) and also
among men (from 7% to 30%, p < 0.0001) and
women (from 8% to 33%, p < 0.0001).
In Hospital C, the number of strains isolated
from PUD patients decreased from 83% to 38%.
No significant difference, however, was noted in
the prevalence of resistance between NUD
patients and PUD patients in 1993 or in 1996
(Figure 2, p < 0.0001). In Hospital C more strains
from non-Western European patients were
included in 1996 than in 1993 (p = 0.04), and the
prevalence of metronidazole resistance was
higher in this group than in the total population.
Exclusion of this patient group still resulted in an
increase in the prevalence among the Western
Europeans (p < 0.0001). The mean age of the
patients from whom H. pylori strains were
isolated in Hospital C was the same in 1993 and
1996 (55 ± 14 [mean ± standard deviation] and
54 ± 16 years, respectively.)
Our study shows a rapidly increasing pre-
valence of metronidazole resistance in H. pylori
in the Netherlands. This increase was observed
in all three hospitals included in the study. Our
results are consistent with the findings of some
investigators (8-13) but not with those of others
(19,20). It confirms our own previous experience
of increasing resistance in this part of the
Netherlands (21,22).
We explored the possibility that the observed
rise in metronidazole resistance was due to some
known confounding factor such as age, sex, endo-
scopic diagnosis, or ethnicity. More H. pylori
strains were isolated from NUD patients in 1996
than in 1993. In 1996, the proportions of women
and foreigners in the examined
populations were also higher. In
contrast with the results of Ching
et al. (23), however, we found that
the prevalence of metronidazole
resistance in NUD patients and
in PUD patients was the same.
Furthermore, the prevalence of
metronidazole resistance was
comparable among men and
women in both 1993 and 1996.
Exclusion of the non-Western
European patients from the analy-
sis still showed a rapid increase
in metronidazole resistance.
Several authors have suggested
that the prevalence of metro-
nidazole resistance is higher in
the young and middle-aged
(19,20,24-26). In our study popu-
lation, however, the mean age
was the same in 1993 and 1996.
The use of different techniques to
measure metronidazole suscep-
tibility could confound the validity
Figure 1. The increase in prevalence of metronidazole resistance of H. pylori
from 1993 to 1996 in three different hospitals. Data presented as percent of
strains that were resistant.
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of our results (26). However, our prospective
study comparing the E-test and disk diffusion, as
well as other studies (27,28), show a very high
intertest agreement when using the above-stated
criteria for metronidazole resistance. We cannot
exclude the possibility that other methodologic
factors are involved. However, because procedures
were standardized and the increase was observed
in three different hospitals, each with its own
laboratory, we consider this unlikely. Therefore,
the observed rapid increase seems real and is
relevant for clinical practice (4-7).
Possible Causes of Resistance
Several authors have suggested that the use
of imidazoles for other indications, such as
gynecologic infections, could account for the
resistance increase (6,22-24,28,29). This would
also explain the higher prevalence of
metronidazole resistance in women that has been
observed in several studies (6,19,21,25). Our
study, however, did not show a
significant difference between
men and women or a more
apparent increase in women.
Moreover, out-of-hospital pre-
scription of metronidazole in the
Netherlands increased only
slightly from 1989 until 1995
(Figure 3). Some authors have
suggested that imidazole-
containing regimens themselves
could be the cause (25,29,30).
However, we consider this
unlikely. First, we excluded all
strains that were isolated after
known anti-H. pylori treatment.
We cannot completely exclude
the possibility that some of the
patients had been treated by
their general practitioner without
our knowledge. We are, however,
confident that this is a rare
occurrence because in our region
most physicians prescribe their
treatment on the basis of
endoscopic findings and culture
of the biopsy specimens, and we
purposely excluded all patients
from whom H. pylori was pre-
viously isolated. In our region,
breath testing is not available for
general practitioners, and
Figure 2. Distribution of metronidazole-resistant strains of H. pylori in 1993
and 1996 in Hospital C. All = total number, NUD = Nonulcer dyspepsia
patients, PUD = peptic ulcer disease patients, nWE = non-Western
Europeans.
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Figure 3. The out-of-hospital use of metronidazole in the Netherlands in the
years 1989 to 1995. Data derived from the Health Insurance Council
(Ziekenfondsraad). Drug Information Project, Amstelveen, the Netherlands.
serologic tests are rarely used. Moreover,
imidazole-containing anti-H. pylori regimens
are highly effective (3,7), and metronidazole
resistance could be induced only in the few
H. pylori strains escaping eradication. Finally,
as infection is rare during adulthood, it is
unlikely that strains rendered resistant in that
way spread in the population (31,32). Therefore,
although general practitioners may have been
treating H. pylori infections more frequently in
recent years, it seems unlikely that this could
have caused the observed fourfold increase in
the prevalence of resistance.
The cause of the rapid increase in metro-
nidazole resistance in H. pylori that we observed
can only be a matter of speculation. Apparently,
metronidazole-resistant H. pylori strains some-
how have a survival advantage, and the increase
in metronidazole resistance may be the result of
some as yet unknown environmental pressure.
Our study suggests that the prevalence of
Resistant
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metronidazole resistance in H. pylori is rapidly
increasing in the Netherlands. The cause of this
increase, however, is still elusive.
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